131 related articles for article (PubMed ID: 2793386)
1. Migratory thrombophlebitis during sandostatin (SMS 201-995, Sandoz) therapy for malignant carcinoid syndrome.
Nathanson L; Sochet A; Williams ME
Invest New Drugs; 1989 Jul; 7(2-3):285-7. PubMed ID: 2793386
[No Abstract] [Full Text] [Related]
2. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of a patient with carcinoid syndrome with SMS-201-995 (octreotide) for 32 months].
Marcos Sánchez F; Juárez Ucelay F; Plaza Díaz R; García Camba L; Durán Pérez-Navarro A
An Med Interna; 1993 Jun; 10(6):309. PubMed ID: 8334213
[No Abstract] [Full Text] [Related]
4. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
[TBL] [Abstract][Full Text] [Related]
5. Carcinoid tumours and the role of Sandostatin.
Woods HF
NATNEWS; 1989 Jul; 26(7):13-5. PubMed ID: 2779638
[No Abstract] [Full Text] [Related]
6. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
Roy RC; Carter RF; Wright PD
Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
[TBL] [Abstract][Full Text] [Related]
7. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
Garland J; Buscombe JR; Bouvier C; Bouloux P; Chapman MH; Chow AC; Reynolds N; Caplin ME
Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
[No Abstract] [Full Text] [Related]
9. Use of somatostatin analog in management of carcinoid syndrome.
Vinik A; Moattari AR
Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
[TBL] [Abstract][Full Text] [Related]
10. Octreotide--a synthetic somatostatin.
Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
[No Abstract] [Full Text] [Related]
11. Successful treatment of unstable angina in malignant carcinoid syndrome using the long-acting somatostatin analogue SMS 201-995 (Sandostatin).
Bluming AZ; Berez RR
Am J Med; 1988 Dec; 85(6):872-4. PubMed ID: 3195610
[No Abstract] [Full Text] [Related]
12. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
14. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
15. Sandostatin (octreotide acetate) injection/Sandoz.
Swartz ML
Gastroenterol Nurs; 1990; 13(2):95-7. PubMed ID: 1963085
[TBL] [Abstract][Full Text] [Related]
16. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
Ranft K; Eibl-Eibesfeldt B
Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
18. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
Wynick D; Bloom SR
J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
[TBL] [Abstract][Full Text] [Related]
19. Octreotide for carcinoid syndrome.
McCrirrick A; Hickman J
Can J Anaesth; 1991 May; 38(4 Pt 1):539-40. PubMed ID: 2065426
[No Abstract] [Full Text] [Related]
20. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
